Drug intelligence / Profile preview

CPO-130

Development stage: Unknown
Lead developer: Conjupro Biotherapeutics
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CPO-130 is a liposomal formulation of the polyene antifungal amphotericin B, developed by CONJ Biotherapeutics. It is currently in the Pre-NDA/ANDA stage for the treatment of systemic fungal infections. Amphotericin B exerts its antifungal activity by binding to ergosterol, a key component of fungal cell membranes. This binding leads to the formation of transmembrane pores, causing the leakage of essential intracellular components and subsequent cell death. The liposomal delivery system is designed to improve the safety profile of amphotericin B, particularly by reducing nephrotoxicity, while maintaining its broad-spectrum antifungal efficacy.

Other names: Liposomal Amphotericin B

Targets

Ergosterol

Beyond the preview

Go deeper on CPO-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPO-130.

Explore the full profile